Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of February 2026, with a specific reporting date of February 12, 2026. The document serves as a public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) in compliance with the UK Market Abuse Regulation. Haleon operates as a global leader in consumer health with a portfolio spanning oral health, vitamins, pain relief, respiratory health, digestive health, and therapeutic skin health.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory notification regarding insider share transactions. The only financial figures disclosed relate to the specific share transactions detailed below:
- Share Price: £3.956 per Ordinary Share.
- Transaction Type: Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two specific share acquisition events on February 10, 2026, executed on the London Stock Exchange (XLON):
- Adrian Morris (General Counsel): Acquired 31 Partnership Shares at £3.956 each and received 31 Matching Shares at no cost. Total aggregated volume: 62 shares.
- Jonathan Workman (President, Europe): Acquired 32 Partnership Shares at £3.956 each and received 32 Matching Shares at no cost. Total aggregated volume: 64 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine compliance filing regarding executive shareholdings.
Investor Verification Checklist
- Verify the total number of shares held by Adrian Morris and Jonathan Workman post-transaction against previous filings.
- Confirm the current market price of Haleon Ordinary Shares (GB00BMX86B70) relative to the transaction price of £3.956.
- Review the terms of the Company's Share Reward Plan to understand the matching share criteria.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.